Nuvectis Pharma (NVCT) Net Income (2021 - 2026)

Nuvectis Pharma (NVCT) has 6 years of Net Income data on file, last reported at -$7.1 million in Q1 2026.

• For the quarter ending Q1 2026, Net Income changed 0.11% year-over-year to -$7.1 million; the trailing twelve-month figure through Mar 2026 stood at -$30.8 million (up 27.89% YoY), and the FY2025 full-year result was -$27.5 million, up 28.69% from the prior year.
• Net Income climbed to -$7.1 million in Q1 2026, from -$8.3 million in the prior quarter.
• In the past five years, Net Income ranged from a high of -$3.9 million in Q1 2022 to a low of -$25.8 million in Q4 2024.
• A 5-year average of -$11.0 million and a median of -$8.3 million in 2025 frame the typical range for Net Income.
• Across the five-year window, Net Income sank 303.28% in 2023 and surged 73.86% in 2024, its largest moves.
• Tracing NVCT's Net Income over 5 years: stood at -$15.3 million in 2022, then plunged by 38.27% to -$21.1 million in 2023, then retreated by 22.09% to -$25.8 million in 2024, then jumped by 67.62% to -$8.3 million in 2025, then climbed by 14.39% to -$7.1 million in 2026.
• Business Quant data shows NVCT's Net Income at -$7.1 million in Q1 2026, -$8.3 million in Q4 2025, and -$8.0 million in Q3 2025.